BIOLIDICS LIMITED
(Company Registration Number: 200913076M)

NOTIFICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE INTENDED DISTRIBUTION OF BIOLIDICS' RAPID TEST KITS FOR NOVEL CORONAVIRUS 2019

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") is pleased to announce that the Company has completed the notification process for the intended distribution of its rapid test kits for Novel Coronavirus 2019 (the "**COVID-19 Rapid Test Kits**") under Section IV.D of the "Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency" ("**Policy D**") of the United States of America ("**USA**") and it has received an acknowledgement from the U.S. Food and Drug Administration (**"FDA"**), a federal agency of the United States Department of Health and Human Services, on the notification process on 9 April 2020 (Singapore time).

Under Policy D, which applies to developers of serology tests that identify antibodies (e.g., IgM, IgG) to SARS-CoV-2 (the virus which causes the disease, the Novel Coronavirus 2019) from clinical specimens, the Company's COVID-19 Rapid Test Kits are only for use by clinical laboratories or healthcare workers for point-of-care testing and not for at home testing. The Company is also required to provide information along the lines of the following in the test reports:

- The test has not been reviewed by the FDA;
- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals;
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status; and
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

The Company wish to highlight that its COVID-19 Rapid Test Kits have not been granted an Emergency Use Authorization by the FDA and the Company is required to complete the listing of its COVID-19 Rapid Test Kits before they can be distributed, marketed and sold to clinical laboratories and healthcare workers for point-of-care testing (the "**Listing**"). The Company is currently in the process of completing the Listing.

More details about Policy D can be found here: https://www.fda.gov/media/135659/download

The Company will make the appropriate announcement(s) as and when there is further material development relating to this matter.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
13 April 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.